Schanzlin D J, Abbott R L, Asbell P A, Assil K K, Burris T E, Durrie D S, Fouraker B D, Lindstrom R L, McDonald J E, Verity S M, Waring G O
Department of Ophthalmology, University of California San Diego, San Diego, California, USA.
Ophthalmology. 2001 Sep;108(9):1688-94. doi: 10.1016/s0161-6420(01)00692-3.
To evaluate the safety and efficacy of Intrastromal Corneal Ring Segments (ICRS) for the correction of myopia.
Nonrandomized, comparative trial.
Patients enrolled in the United States Food and Drug Administration phase II and phase III clinical trials of the ICRS had best spectacle-corrected visual acuity (BSCVA) of 20/20 or better, myopia of -1.00 to -3.50 diopters (D), and a cylindrical correction of 1.00 D or less as measured by manifest refraction.
Surgical correction of myopia with an ICRS.
Efficacy was assessed by predictability of refractive outcome (deviation from predicted cycloplegic refraction spherical equivalent), stability of refractive effect, and postoperative uncorrected visual acuity. Safety was assessed by adverse events, maintenance or loss of preoperative BSCVA, and induced manifest refraction cylinder.
Four hundred fifty-two patients were enrolled at 11 investigational sites in both studies. Of the 454 surgical attempts, 449 received an ICRS in one eye (0.25, 0.30, and 0.35 mm in 148, 151, and 150 eyes, respectively). First surgeries were attempted in 452 patients. An ICRS was successfully implanted in 447 initial eyes, and 5 surgeries were discontinued. Of the five discontinued surgeries, three patients subsequently exited from the study, and two patients went on to have the ICRS implanted in the second eye, bringing the total number of successful implants to 449 patient eyes. Month 24 postoperative follow-up was completed on 358 patients (80%). At month 24, 328 of 354 eyes (93%) were within +/-1.00 D of predicted refractive outcome. Refraction changed by 1 D or less in 97% of eyes (421/435) between 3 and 6 months after implantation and in 99% (343/348) between months 18 and 24. Before surgery, 87% of eyes (390/448) saw worse than 20/40 uncorrected; 24 months after surgery, 55% of eyes (196/358) saw 20/16 or better, 76% (271/358) saw 20/20 or better, and 97% (346/358) saw 20/40 or better. Although two eyes (2/358; 0.5%) lost two or more lines of BSCVA at 24 months; visual acuity in both was 20/20 or better. Intraoperative complications included anterior corneal surface perforation (three eyes) and anterior chamber perforations (two eyes, one during an attempted exchange procedure); all healed spontaneously without suturing and without loss of BSCVA. The ICRS was repositioned in five eyes to increase correction. Postoperative complications in one eye each were infectious keratitis, shallow segment placement, and loss of two lines of BSCVA at two or more consecutive examinations (subsequently regained).
The ICRS safely, predictably, and effectively reduced or eliminated myopia of -1.00 to -3.50 D. The refractive effect was stable over time.
评估角膜基质内环形片段(ICRS)矫正近视的安全性和有效性。
非随机对照试验。
入选美国食品药品监督管理局ICRS II期和III期临床试验的患者,最佳矫正视力(BSCVA)为20/20或更好,近视度数为-1.00至-3.50屈光度(D),通过显然验光测量的柱镜矫正度数为1.00 D或更低。
采用ICRS进行近视手术矫正。
通过屈光结果的可预测性(与预测的睫状肌麻痹验光球镜等效值的偏差)、屈光效果的稳定性和术后裸眼视力评估疗效。通过不良事件、术前BSCVA的维持或丧失以及诱导的显然验光柱镜评估安全性。
两项研究中,11个研究地点共纳入452例患者。在454次手术尝试中,449例患者单眼植入了ICRS(148眼植入0.25 mm、151眼植入0.30 mm、150眼植入0.35 mm)。452例患者首次尝试手术。447只初始眼成功植入ICRS,5例手术中断。在5例中断的手术中,3例患者随后退出研究,2例患者继续在第二眼植入ICRS,使成功植入的总数达到449只患眼。358例患者(80%)完成了术后24个月的随访。在术后24个月时,354眼中的328眼(93%)屈光结果在预测值的±1.00 D范围内。植入后3至6个月,97%的眼(421/435)屈光变化1 D或更小,18至24个月间为99%(343/348)。术前,87%的眼(390/448)裸眼视力低于20/40;术后24个月,55%的眼(196/358)视力达到20/16或更好,76%(271/35)视力达到20/20或更好,97%(346/358)视力达到20/40或更好。尽管2只眼(2/358;0.5%)在24个月时BSCVA下降了两行或更多行;但两者的视力均为20/20或更好。术中并发症包括角膜前表面穿孔(3只眼)和前房穿孔(2只眼,其中1只在尝试更换手术过程中发生);均自行愈合,无需缝合,且BSCVA未丧失。5只眼中重新调整了ICRS位置以增加矫正量。单眼术后并发症分别为感染性角膜炎、片段植入过浅以及在连续两次或更多次检查中BSCVA下降两行(随后恢复)。
ICRS安全、可预测且有效地降低或消除了-1.00至-3.50 D的近视。屈光效果随时间稳定。